Bedaquiline, delamanid, linezolid and clofazimine for the treatment of rifampicin- and fluoroquinolone-resistant tuberculosis (endTB-Q): a Phase 3, open-label, multicentre, randomised, controlled, stratified, non-inferiority trial

Guglielmetti L*, Khan U*, Velásquez G*, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektasov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, De Jong BC, Van Luong D, Ferlazzo G, Kirakosyan O, Kunda MK, Lachenal N, Lecca L, McIlleron HM, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Van Nguyen D, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Huu Pham T, Dat PT, Phan HTT, Phillips PP, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung K, Tamirat M, Vargas D, Rich ML**, Varaine F**, Mitnick CD**, and endTB-Q Clinical Trial Team. Bedaquiline, delamanid, linezolid and clofazimine for the treatment of rifampicin- and fluoroquinolone-resistant tuberculosis (endTB-Q): a Phase 3, open-label, multicentre, randomised, controlled, stratified, non-inferiority trial. SSRN [Preprint]. 2025.